Since its development as a HIV entry inhibitor, CCR5 has been used as a target in several clinical studies of HIV infection as well as in other applications, including auto-immune diseases, cancer and transplantation [15], [29]–[34]. Here, CCR5 is linked to HIV infectious disease.